Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Here’s Why

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) gapped up prior to trading on Tuesday . The stock had previously closed at $31.85, but opened at $33.15. Otsuka shares last traded at $33.2362, with a volume of 3,518 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. The Goldman Sachs Group lowered Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Otsuka has a consensus rating of “Hold”.

Otsuka Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The company has a market capitalization of $35.77 billion and a PE ratio of 14.05. The firm’s fifty day simple moving average is $34.60 and its 200 day simple moving average is $32.34.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, research analysts predict that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.